Crossmark

Niclosamide, an antihelmintic drug, enhances efficacy of PD-1/PD-L1 immune checkpoint blockade in non-small cell lung cancer

Crossref DOI link: https://doi.org/10.1186/s40425-019-0733-7

Published Online: 2019-09-11

Published Print: 2019-12

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Luo, Fan

Luo, Min

Rong, Qi-Xiang

Zhang, Hong

Chen, Zhen

Wang, Fang

Zhao, Hong-Yun

Fu, Li-Wu
Funding

Funding for this research was provided by:

Medical Science and Technology Foundation of Guangdong Province (CN) (No. 2016A030312014)

Guangzhou Science and Technology Program (No. 201707010048)

Scientific and Technological Leading Talent Project of Guangdong Province (2015)

National Natural Science Foundation of China (81673463, 81503092, 81703545)
License Information

Text and Data Mining valid from 2019-09-11
More Information

Article History

Received: 29 March 2019

Accepted: 5 September 2019

First Online: 11 September 2019

Ethics approval

: All in vivo experiments were approved by the Guangdong Provincial Animal Care and Use Committee.

: Not applicable

: The authors declare that they have no competing interests.